Researchers from centers in Milan, Italy, suggest that adopting a dual approach to therapy for Charcot-Marie-Tooth type 2A (CMT2A) disease is effective in two model systems and may lead to an effective treatment for patients.
News News Daily digests from key neurology conferences, written by on-site medical journalists.